TransMedics Group, Inc. $TMDX Shares Bought by Bessemer Group Inc.

Bessemer Group Inc. grew its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 38.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 45,821 shares of the company’s stock after purchasing an additional 12,812 shares during the period. Bessemer Group Inc. owned approximately 0.13% of TransMedics Group worth $4,555,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Allspring Global Investments Holdings LLC lifted its stake in shares of TransMedics Group by 11.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 6,465 shares of the company’s stock valued at $649,000 after purchasing an additional 652 shares during the period. Regency Capital Management Inc. DE acquired a new position in TransMedics Group during the first quarter worth about $2,172,000. Geneos Wealth Management Inc. purchased a new position in TransMedics Group in the first quarter valued at about $3,045,000. Principal Financial Group Inc. increased its holdings in TransMedics Group by 19.4% in the first quarter. Principal Financial Group Inc. now owns 231,433 shares of the company’s stock valued at $23,007,000 after buying an additional 37,656 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its position in shares of TransMedics Group by 97.0% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 16,779 shares of the company’s stock valued at $1,668,000 after acquiring an additional 8,260 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Stock Down 0.7%

TMDX opened at $73.47 on Tuesday. The company has a quick ratio of 6.19, a current ratio of 6.74 and a debt-to-equity ratio of 1.70. The firm has a market cap of $2.54 billion, a P/E ratio of 16.70 and a beta of 1.89. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00. The business’s fifty day simple moving average is $71.02 and its 200 day simple moving average is $104.11.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.30 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). The company had revenue of $173.93 million for the quarter, compared to analysts’ expectations of $174.44 million. TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.70 EPS. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1.92 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the sale, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 6.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. UBS Group reaffirmed a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Canaccord Genuity Group restated a “buy” rating and issued a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. TD Cowen restated a “buy” rating and issued a $120.00 price target on shares of TransMedics Group in a research report on Wednesday, July 1st. Needham & Company LLC cut their price target on TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research note on Wednesday, May 6th. Finally, Zacks Research lowered shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $134.50.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.